Experience with multidrug therapy in paucibacillary leprosy.

Area of Science:

• Dermatology
• Infectious Diseases
• Microbiology

Background:

• Leprosy remains a significant global health challenge, particularly the paucibacillary form.
• Effective multidrug therapy (MDT) is crucial for leprosy control and eradication.
• The World Health Organization (WHO) has established specific MDT regimens for different leprosy types.

Purpose of the Study:

• To compare the efficacy and acceptability of two multidrug regimens for paucibacillary leprosy.
• To evaluate the impact of adding clofazimine to the standard WHO (1982) regimen.
• To assess the adequacy of the WHO (1982) recommended treatment duration.

Main Methods:

• Eighty paucibacillary leprosy patients were randomized into two groups.
• Regimen I: WHO (1982) MDT (Dapsone + monthly Rifampicin) for 6 months.
• Regimen II: WHO (1982) MDT + Clofazimine (100 mg alternate days) for 6 months, followed by Dapsone monotherapy for up to one year.
• Efficacy, acceptability, and side effects were monitored for one year; histopathological assessments were performed.

Main Results:

• The addition of clofazimine to the WHO (1982) recommended regimen showed no significant added benefit in treating paucibacillary leprosy.
• Histopathological assessments indicated that the duration of the WHO (1982) recommended multidrug therapy was inadequate for a considerable number of patients.
• Both regimens were generally acceptable, with observed side effects requiring monitoring.

Conclusions:

• The current WHO (1982) multidrug regimen for paucibacillary leprosy may require adjustments in duration.
• Adding clofazimine to the standard WHO (1982) regimen does not appear to enhance treatment outcomes.
• Further research into optimized MDT durations and combinations for paucibacillary leprosy is warranted.